文献速递临床免疫质量管理与危急值临床生化

将神经丝轻链检测转化至临床实践:多学科实施路线图

Translating neurofilament light chain testing into clinical practice: a multidisciplinary implementation roadmap.
PubMed 文献 · Clin Chem Lab Med · 2026-03-13

本文是一篇多学科立场文件,提出将循环神经丝轻链(NfL)检测转化至常规临床实践的实施路线图,整合分析、解释与组织维度。文件总结NfL作为神经轴索损伤生物标志物的生物学基础与临床证据,比较免疫分析技术差异,强调分析前标准化与实验室间协调,并指出年龄、BMI、肾功能等混杂因素影响解读。临床层面聚焦多发性硬化(MS)中NfL用于疾病活动预测与监测、治疗决策及疗效评估,提出实验室验证、结构化报告与国家神经照护路径对接的实施模型。

要点

  • NfL是跨神经系统疾病的高敏感神经轴索损伤生物标志物。
  • 解读需考虑年龄、BMI、肾功能等混杂因素,建议使用年龄校正Z评分与纵向归一化。
  • MS中NfL可用于疾病活动预测与监测、治疗决策及疗效评估。

核心结论

  • NfL转化为临床使用需要协调的分析程序、跨学科教育与可持续治理框架。
  • 实现上述措施后,NfL将成为精准神经病学与神经退行性监测的基石生物标志物。

研究设计与样本

  • 本文为多学科立场文件,整合分析、解释与组织维度提出NfL临床实施路线图。

主要发现

  • NfL在MS、ALS、AD及非典型帕金森综合征等疾病中作为神经轴索损伤标志物得到广泛验证。
  • 免疫分析技术比较识别出优势与关键变异来源。
  • 年龄、BMI、肾功能与合并症显著影响解读,支持年龄校正Z评分、百分位与纵向归一化用于患者层面评估。
  • 临床聚焦MS中NfL用于疾病活动预测与监测、治疗决策与治疗反应评估。
  • 提出将血NfL与MRI、GFAP及其他生物标志物整合作为生物标志物驱动精准神经病学的核心策略。

关键数值与推荐

  • 操作指南强调分析前标准化、实验室间协调与参加质量控制方案的必要性。
  • 实施模型涵盖实验室验证、结构化报告与与国家神经照护路径对接。
  • 优先行动包括监管资格认定、建立国际参考物质与开展务实真实世界试验。

临床怎么用

  • 在MS中可用NfL预测与监测疾病活动、辅助治疗决策与评估治疗反应。
  • 患者层面解读应结合年龄校正Z评分、百分位与纵向归一化,并考虑年龄、BMI、肾功能与合并症。
  • 实验室应推动分析前标准化、室间协调并参与质控方案,报告需结构化。
  • 可将血NfL与MRI、GFAP等生物标志物整合用于精准神经病学评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neurofilament light chain (NfL) has been identified as a sensitive and broadly validated biomarker of neuroaxonal injury across multiple neurological conditions, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and atypical parkinsonian syndromes. This position paper provides a multidisciplinary roadmap for translating circulating NfL testing into routine clinical practice, integrating analytical, interpretative, and organizational dimensions. It summarizes the biological basis and clinical evidence supporting NfL as a diagnostic, prognostic, and monitoring tool, emphasizing its high sensitivity to neuroaxonal injury across both acute inflammatory and chronic degenerative processes. Comparative analysis of immunoassay technologies identifies strengths and critical sources of variability, while operational guidelines highlight the need for pre-analytical standardization, inter-laboratory harmonization, and participation in quality control schemes. Confounders such as age, BMI, renal function, and comorbidities are shown to significantly influence interpretation, supporting the use of age-adjusted Z-scores, percentiles, and longitudinal normalization for accurate patient-level evaluation. From a clinical standpoint, the paper focuses on practical indications for NfL testing in MS, recommending its use for disease activity prediction and monitoring, treatment decisions and treatment response assessment. Integration of blood NfL with magnetic resonance imaging (MRI), glial fibrillary acidic protein (GFAP) and other biomarkers measurement is proposed as a core strategy for biomarker-driven precision neurology. The authors outline an implementation model encompassing laboratory validation, structured reporting and alignment with national neurological care pathways. They conclude that the transition of NfL into clinical use requires harmonized analytical procedures, interdisciplinary education, and sustainable governance frameworks. Priority actions include regulatory qualification, establishment of international reference materials, and development of pragmatic real-world trials to consolidate its clinical utility. When these measures are achieved, NfL will represent a cornerstone biomarker for precision neurology and neurodegeneration monitoring.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Furlan R, Di Sapio A, Ferraro D, et al. Translating neurofilament light chain testing into clinical practice: a multidisciplinary implementation roadmap. Clin Chem Lab Med. 2026. PMID: 41831326. doi:10.1515/cclm-2025-1743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。